Publication | Open Access
The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance
13
Citations
34
References
2020
Year
Hematological MalignancyLenalidomide ResistanceNovel TherapyImmunologyHematologyMedicineCell BiologyOvercomes BortezomibMyeloid Neoplasia
| Year | Citations | |
|---|---|---|
Page 1
Page 1